Form 4: Nautilus Biotechnology Director Matthew Posard Granted 45,000 Stock Options

Nautilus Biotechnology, Inc. Director Matthew L. Posard was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Summary

• Matthew L. Posard, a Director of Nautilus Biotechnology, Inc. (NAUT), was granted 45,000 stock options.
• The transaction date for this grant was June 23, 2025.
• The exercise price for these stock options is $0.6951 per share.
• The options are subject to a vesting schedule where one-twelfth (1/12th) of the shares vest on a monthly basis following the grant date, contingent on Mr. Posard's continuous status as a 'Service Provider' under the Issuer's 2021 Equity Incentive Plan.
• The expiration date for these stock options is June 23, 2035.
• Following this transaction, Mr. Posard beneficially owns 45,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a routine stock option grant to a director, which is a standard compensation practice and does not indicate significant positive or negative news regarding the company's operational or financial performance.

Positives

• The stock option grant aligns the director's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• This is a standard compensation practice designed to incentivize and retain key personnel, including directors.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though the amount is relatively small.

Risks

• The value of the stock options is dependent on the future market price of Nautilus Biotechnology's common stock; if the stock price does not exceed the exercise price, the options may not be profitable.
• The vesting of the options is contingent on Mr. Posard's continuous service as a 'Service Provider,' meaning unvested options would be forfeited if his service terminates.

Future Outlook

This document primarily reports a past transaction (option grant) and outlines the future vesting schedule of those options. It does not provide forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This Form 4 filing details an individual insider transaction (a stock option grant to a director) and does not provide information on broader industry trends or competitive landscape. Such grants are common practice across various industries, including biotechnology, for executive and director compensation.

Corporate Governance

Related Party Transactions

• The grant of 45,000 stock options to Matthew L. Posard, a Director of Nautilus Biotechnology, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from incentivized leadership.
• Director (Matthew L. Posard): Receives equity-based compensation, aligning personal financial interests with the company's stock performance.

Next Steps

• The granted stock options will vest monthly over a one-year period, subject to the director's continuous service.
• The director may choose to exercise the vested options at any time before their expiration date of June 23, 2035.

Key Dates

Keywords

Nautilus Biotechnology, NAUT, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Biotechnology